Scholarlink

Objective <p>Many clinical trials indicate that flaxseed supplementation may exhibit a significant antihypertensive effect, although the findings are inconsistent. This meta-analysis was conducted to provide a more accurate assessment of the impact of flaxseed supplementation on blood pressure in patients with metabolic diseases.</p> Methods <p>We conducted a comprehensive search of international databases, such as Scopus, PubMed, Web of Science, and Cochrane Central, with data collection continuing until July 2024. We employed a random-effects model for calculating weighted mean differences (WMDs) to ensure robust analysis.</p> Results <p>Meta-analysis of 18 trials (comprising 22 treatment arms) with 1,209 participants revealed significant reductions in both systolic (WMD: -4.30 mmHg; 95% CI: -6.64 to -1.96, <i>p</i> &lt; 0.001; I<sup>2</sup> = 95.2%, <i>p</i> &lt; 0.001) and diastolic blood pressure (WMD = -2.50 mmHg; 95% CI: -3.88, -1.12, <i>p</i> &lt; 0.001; I<sup>2</sup> = 95.0%, <i>p</i> &lt; 0.001) following flaxseed supplementation. More significant effects on SBP and DBP were found in trials with an intervention duration of 10–20 weeks, whole flaxseed, subjects with BMI 25–30&#xa0;kg/m<sup>2</sup>, and in patients with hypertension.</p> Conclusion <p>Flaxseed products have been shown to lower both systolic and diastolic blood pressure levels significantly. Together with traditional medicine, flaxseed may be an effective supplement for hypertension treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Can flaxseed supplementation alleviate blood pressure in patients with metabolic diseases? Evaluating the strength of evidence using a meta-analysis and GRADE approach

  • 期刊论文

  • 发表日期：

    2025年6月12日

查看全文
  • Vali Musazadeh,
  • Niloofar Hamidi,
  • Mahsa Mahmoudinezhad,
  • Ali Jafari,
  • Farzad Shidfar

摘要

Objective

Many clinical trials indicate that flaxseed supplementation may exhibit a significant antihypertensive effect, although the findings are inconsistent. This meta-analysis was conducted to provide a more accurate assessment of the impact of flaxseed supplementation on blood pressure in patients with metabolic diseases.

Methods

We conducted a comprehensive search of international databases, such as Scopus, PubMed, Web of Science, and Cochrane Central, with data collection continuing until July 2024. We employed a random-effects model for calculating weighted mean differences (WMDs) to ensure robust analysis.

Results

Meta-analysis of 18 trials (comprising 22 treatment arms) with 1,209 participants revealed significant reductions in both systolic (WMD: -4.30 mmHg; 95% CI: -6.64 to -1.96, p < 0.001; I2 = 95.2%, p < 0.001) and diastolic blood pressure (WMD = -2.50 mmHg; 95% CI: -3.88, -1.12, p < 0.001; I2 = 95.0%, p < 0.001) following flaxseed supplementation. More significant effects on SBP and DBP were found in trials with an intervention duration of 10–20 weeks, whole flaxseed, subjects with BMI 25–30 kg/m2, and in patients with hypertension.

Conclusion

Flaxseed products have been shown to lower both systolic and diastolic blood pressure levels significantly. Together with traditional medicine, flaxseed may be an effective supplement for hypertension treatment.